SecBot SecBot
PRESS-RELEASE ·Filed May 14, 2026

CMMB

Chemomab Therapeutics Ltd.
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The stock is a binary catalyst play on partnership news or Phase 3 trial updates. With $8M cash lasting ~3 more quarters and no revenue, the company must secure a partnership or financing by mid-2027. Monitor EASL 2026 presentations (May 30) for any partnership announcement or data that could trigger a re-rating.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.70
T+0 close · May 14, 2026 · via day close
Latest settled
+11.18%
T+60 · $1.89
Vs SPY
+7.59%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 14 $1.70entry
  2. T+1 · 6mo ago −2.35%α −1.13% · $1.66
  3. T+5 · 6mo ago +7.06%α +7.78% · $1.82
  4. T+20 · 5mo ago −2.94%α −2.08% · $1.65
  5. T+60 · 3mo ago +11.18%α +7.59% · $1.89
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Chemomab reported Q1 2026 net loss of $1.8M ($0.003/share) vs $3.3M in Q1 2025, with cash burn reduced to $2.4M. The company highlighted new biomarker data from its Phase 2 SPRING trial suggesting nebokitug may benefit PSC patients with coexisting IBD, and continues pursuing partnership discussions. Cash runway extends through Q1 2027, but at a $13M market cap the stock remains a binary-option on partnership or Phase 3 outcomes.

Key Financial Metrics

EPS
−$0.00
est $0.00
Rating
in line

Key Facts

  • Q1 2026 net loss of $1.8M vs $3.3M in Q1 2025; R&D expenses fell to $0.9M from $2.5M as Phase 2 SPRING trial wound down
  • Cash, equivalents and short-term deposits of $8.0M as of March 31, 2026, down from $10.4M at year-end 2025; runway through Q1 2027
  • New biomarker data from SPRING trial presented at DDW 2026 and upcoming EASL 2026 suggest nebokitug modulates gut-liver inflammatory pathways relevant to PSC-IBD comorbidity
  • Company continues advancing multiple partnering options for nebokitug; no definitive partnership announced
  • FDA alignment on Phase 3 registration trial design for PSC previously achieved; nebokitug has FDA/EMA Orphan Drug and FDA Fast Track designations for PSC

Financial Impact

Cash burn of ~$2.4M in Q1 2026; cash runway of ~$8M expected to fund operations through Q1 2027

cashnet lossR&D expenses

Risk Factors

  • Cash runway only through Q1 2027; dilutive financing likely if partnership does not materialize
  • No approved products or revenue; full reliance on nebokitug clinical and regulatory success
  • Phase 3 PSC trial carries inherent clinical and regulatory risk; biomarker data may not translate to clinical endpoints
  • Low liquidity ($13M market cap) amplifies price volatility on any news

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3294834

US Market Status

Market Closed · Opens in 9h 23m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026